The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.